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Abstract 45 
          Endothelial cell (EC) barrier disruption induced by inflammatory agonists such as 46 
thrombin leads to potentially lethal physiological dysfunction such as alveolar flooding, 47 
hypoxemia and pulmonary edema. Thrombin stimulates paracellular gap and F-actin stress fiber 48 
formation, triggers actomyosin contraction and alters EC permeability through multiple 49 
mechanisms that include protein kinase C (PKC) activation. We previously have shown that the 50 
ezrin, radixin, and moesin (ERM) actin-binding proteins differentially participate in S1P-induced 51 
EC barrier enhancement. Phosphorylation of a conserved threonine residue in the C terminus of 52 
ERM proteins causes conformational changes in ERM to unmask binding sites and is considered 53 
a hallmark of ERM activation.  In the present study we test the hypothesis that ERM proteins are 54 
phosphorylated on this critical threonine residue by thrombin-induced signaling events and 55 
explore the role of the ERM family in modulating thrombin-induced cytoskeletal rearrangement 56 
and EC barrier function. Thrombin promotes ERM phosphorylation at this threonine residue 57 
(Ezrin-567, Radixin-564, Moesin-558) in a PKC-dependent fashion and induces translocation of 58 
phosphorylated ERM to the EC periphery. Thrombin-induced ERM threonine phosphorylation is 59 
likely synergistically mediated by protease-activated receptors PAR1 and PAR2. Using the 60 
siRNA approach, depletion of either moesin alone, or of all three ERM proteins, significantly 61 
attenuates thrombin-induced increase in EC barrier permeability (TER), cytoskeletal 62 
rearrangements, paracellular gap formation and accumulation of di-phospho-MLC. In contrast, 63 
radixin depletion exerts opposing effects on these indices. These data suggest that ERM proteins 64 
play important differential roles in the thrombin–induced modulation of EC permeability, with 65 
moesin promoting barrier dysfunction and radixin opposing it.  66 
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Introduction 92 
         The pulmonary vascular endothelium serves as a semi-selective barrier between circulating 93 
blood and surrounding tissues. Endothelial cell (EC) barrier integrity is therefore critical to tissue 94 
and organ function. Disruption of the endothelial barrier by inflammatory mediators such as 95 
thrombin, histamine, and LPS leads to potentially lethal physiological dysfunction such as 96 
hypoxemia, atherosclerosis and pulmonary edema, a hallmark of acute lung injury and its more 97 
severe form, acute respiratory distress syndrome (12). Therefore, the preservation of vascular 98 
endothelial cell (EC) barrier integrity has the potential for profound clinical impact. Multiple 99 
studies have demonstrated that inflammation-induced EC barrier dysfunction involves 100 
cytoskeletal rearrangement, contraction of endothelial cells and intercellular gap formation, 101 
leading to increased paracellular permeability (18, 20, 55, 65). Thrombin, a multifunctional 102 
serine protease, proteolytically cleaves and activates PAR1, a member of a unique class of G 103 
protein–coupled receptors activated by proteolytic cleavage of their extracellular N-terminal 104 
domains and expressed at the surfaces of EC (43, 66). Thrombin can transactivate PAR2 through 105 
PAR1 in cultured human umbilical vein EC (HUVECs) (48). PAR1 and PAR2 activate 106 
heterotrimeric G-proteins Gq, G12/13, and Gi, all of which are involved in permeability regulation 107 
(42). Activation of Gq mobilizes Ca2+ and activates PKC, RhoA, and EC contraction, resulting in 108 
endothelial barrier disruption. 109 
         The widely distributed ERM family of membrane-associated proteins (ezrin, radixin, 110 
moesin) regulates the structure and function of specific domains of the cell cortex [reviewed in 111 
(2, 14, 46)].  The ERM proteins are actin-binding linkers that connect the actin cytoskeleton to 112 
the plasma membrane. This linker function makes ERM proteins essential for many fundamental 113 
cellular processes including cell adhesion, determination of cell shape, motility, cytokinesis and 114 
integration of membrane transport with signaling pathways (14, 47, 71). The three ERM proteins 115 
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share a high level of amino acid identity (70-85%) (14), and prior to activation exist in an auto-116 
inhibited conformation in which the actin-binding C-terminal tail binds and masks the N-117 
terminal FERM domain (band 4.1, ezrin, radixin, moesin homology domains) (50). The 118 
activation state of ERM proteins is tightly regulated by phosphorylation events. Binding of the 119 
protein to membrane lipid phosphatidylinositol 4,5-bisphosphate (PIP2) (15) and subsequent 120 
phosphorylation of a conserved C-terminal threonine (T567 in ezrin, T564 in radixin, T558 in 121 
moesin) (21, 41, 50) are believed to disrupt the intramolecular association, thus unmasking sites 122 
for interactions with other proteins. In addition, phosphorylation of ezrin on other residues may 123 
be required to direct specific targeted effects in cells (29, 36, 57). Several kinases have been 124 
implicated in regulating ERM protein function through phosphorylation of the C-terminal 125 
threonine residue (3, 10, 35, 40, 59, 67).  However, the identity of kinases that directly 126 
phosphorylate ERM in many cells remains to be clearly defined (14, 29).  127 
         ERM proteins also associate with cytoplasmic signaling molecules in cellular processes 128 
that require membrane cytoskeletal reorganization. ERM proteins appear to act both downstream 129 
and upstream of the Rho family of GTPases, which regulates remodeling of the actin 130 
cytoskeleton (14, 29). However, information is limited concerning the possible role of ERM 131 
proteins in the remodeling of endothelial cytoskeleton in response to different agonists. Koss and 132 
coworkers (35) demonstrated that ERM proteins are phosphorylated on C-terminal threonine 133 
residues by TNF-α-induced signaling events and likely play important roles in modulating the 134 
cytoskeletal changes and permeability increases in human pulmonary microvascular EC. We 135 
previously have shown that PKC isoforms are required for ERM phosphorylation in human 136 
pulmonary EC induced by the potent barrier protective factor, platelet-derived phospholipid 137 
sphingosine-1 phosphate (S1P) (1). Further, we previously demonstrated that ERM proteins, 138 
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despite their structural similarities and reported functional redundancy, differentially modulate 139 
S1P-induced changes in lung EC cytoskeleton and permeability (1). In the present study, we 140 
explored the potential involvement of ERM proteins in modulating thrombin-induced 141 
cytoskeletal rearrangement and EC barrier function.  142 
 143 
Materials and methods 144 
 145 
Reagents  146 
         Thrombin was obtained from Sigma Co. (St. Louis, MO). Antibodies (Ab) were obtained as 147 
follows:  mouse monoclonal Ab against β-Tubulin (Covance, Berkeley, CA), rabbit polyclonal 148 
di-phospho-MLC and rabbit polyclonal phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin 149 
(Thr558) Ab (Cell Signaling, Danvers, MA), ezrin specific mouse monoclonal Ab (Invitrogen 150 
Life Technologies, Carlsbad, CA), rabbit monoclonal anti-radixin Ab (Sigma, St. Louis, MO), 151 
mouse monoclonal anti-moesin Ab (BD Biosciences, San Jose, CA), mouse monoclonal anti-152 
thrombin receptor WEDE15 blocking Ab (Beckman Coulter, Indianapolis, IN), mouse 153 
monoclonal thrombin R (ATAP2) blocking Ab (Santa Cruz Biotech., Santa Cruz, CA), Texas red 154 
phalloidin and Alexa 488-, Alexa 594-conjugated secondary Ab (Molecular Probes, Eugene, 155 
OR). ROCK inhibitors Y-27632 and H-1152, PKC inhibitors Ro-31-7549, Bisindolylmaleimide 156 
I, and Go 6976, p38 kinase inhibitor SB203580 were purchased from Calbiochem (San Diego, 157 
CA), Ca(2+) chelator BAPTA-AM was obtained from Sigma (St. Louis, MO), PI3 Kinase 158 
inhibitor LY294002 and MLCK inhibitor ML-7, PAR1 selective agonist TFLLR-NH2, PAR2 159 
selective agonist SLIGRL-NH2 and reversed amino acid sequence control peptides RLLFT-NH2 160 
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and LRGILS-NH2 were obtained from TOCRIS (Bristol, UK). Unless specified, biochemical 161 
reagents were obtained from Sigma.  162 
 163 
Cell culture  164 
         Human pulmonary artery endothelial cells (HPAEC) were obtained from Lonza Inc. 165 
(Walkersville, MD) and were utilized at passages 5–9.  166 
 167 
Measurement of transendothelial electrical resistance 168 
          Cellular barrier properties were measured using an electrical cell substrate impedance 169 
sensing system (ECIS) (Applied Biophysics, Troy, NY). HPAEC were seeded onto plates with 170 
small gold electrodes (10–4 cm2) and measurements of transendothelial electrical resistance 171 
(TER) across confluent HPAEC monolayers were performed as previously described (6, 19, 65). 172 
 173 
Real-time quantitative RT–PCR 174 
         Endogenous transcript levels of ezrin (EZR), radixin (RDX), and moesin (MSN) in HPAEC 175 
were measured in a 384-well PCR plate with an ABI 7900 HT Fast Real-Time PCR System 176 
(Applied Biosystems, Carlsbad, CA). Total RNA (1 µg) were first reverse transcribed using 177 
Superscript II Reverse Transcriptase (Invitrogen Life Technologies) and random hexamer 178 
primers (Applied Biosystems) to generate cDNA. Quantitative Real Time-PCR (qRT-PCR) was 179 
then performed using the Assay-on-Demand system (Hs00185574_m1 (EZR); Hs00267954_m1 180 
(RDX); Hs00792607_mH (MSN) from Applied Biosystems according to the manufacturer's 181 
protocol. Purity and specificity of all products were confirmed by omitting the reverse 182 
transcriptase or template. Analysis of results is based on the average of triplicates. The standard 183 
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curve method was used for relative quantitation of target gene expression. Further information on 184 
the method can be found on User Bulletin #2 on the ABI website. 185 
 186 
Depletion of specific EC proteins via siRNA 187 
 188 
         To reduce the content of individual EC proteins, cultured EC were treated with specific 189 
siRNA duplexes, which guide sequence-specific degradation of the homologous mRNA (13). 190 
The following validated siRNAs were obtained from QIAGEN (Valencia, CA) in ready-to-use, 191 
desalted, and duplexed form: duplex of sense 5′-CACCGUGGGAUGCUCAAAGdTdT-3′ and 192 
antisense 5′-CUUUGAGCAUCCCACGGUGdTdT-3′ siRNA was used for targeting sequences 193 
that are part of the coding region for Homo sapiens ezrin: 5′-194 
AACACCGTGGGATGCTCAAAG-3′, duplex of sense 5′-195 
GAAAUAACCCAGAGACUCUdTdT-3′ and antisense 5′-196 
AGAGUCUCUGGGUUAUUUCdTdT-3′ was used for targeting sequences that are part of the 197 
coding region for Homo sapiens radixin: 5′-AAGAAATAACCCAGAGACTCT-3′, and duplex 198 
of sense 5′-GGGAUGUCAACUGACCUAAdTdT-3′ and  antisense  5′-199 
UUAGGUCAGUUGACAUCCCdTdG-3′ was used for targeting sequences that are part of the 200 
coding region for Homo sapiens moesin: 5′-CAGGGATGTCAACTGACCTAA-3′. Duplex of 201 
sense 5′-AGAGCUAAG-UAGAUGUGUAdTdT-3′ and antisense 5′-202 
UACACAUCUACUUAGCUCUdTdG-3′ siRNA was used for targeting sequences that are part 203 
of the coding region for Homo sapiens PKCβI: 5′-CAAGAGCTAAGTAGATGTGTA-3′, duplex 204 
of sense 5′-GAAGCAUGACAGCAUUAAA dTdT-3′ and antisense 5′-205 
UUUAAUGCUGUCAUGCUUCdCdG-3′ was used for targeting sequences that are part of the 206 
coding region for Homo sapiens PKCζ: 5′-CGGAAGCATGACAGCATTAAA-3′, duplex of 207 
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sense 5′-CUCUACCGUGCCACGUUUUdTdT-3′ and antisense 5′-208 
AAAACGUGGCACGGUAGAGdTdT-3′ was used for targeting sequences that are part of the 209 
coding region for Homo sapiens PKCδ: 5′-AACTCTACCGTGCCACGTTTT-3′, duplex of sense 210 
5′-CAAGAAGUGUAUUGAUAAAdTdT-3′ and antisense 5′-211 
UUUAUCAAUACACUUCUUGdTdG-3′ was used for targeting sequences that are part of the 212 
coding region for Homo sapiens PKCθ: 5′-CACAAGAAGTGTATTGATAAA-3′, duplex of 213 
sense 5’- CGGAAACACCCGUACCUUAdTdT-3’ and antisense 5’- 214 
UAAGGUACGGGUGUUUCCGdTdG-3’ were used for targeting sequences that are part of the 215 
coding region for Homo sapiens PKCε: 5’- CACGGAAACACCCGTACCTTA-3’. Silencer 216 
select pre-designed siRNA duplex (Life Technologies, Grand Island, NY) of sense 5’-217 
CCCGUAACCUAAUUCCUAUdTdT-3’ and antisense 5’-218 
AUAGGAAUUAGGUUACGGGdCdC-3’ was used for targeting sequences that are part of the 219 
coding region for Homo sapiens PKCγ: 5’- GGCCCGTAACCTAATTCCTAT-3’. Non-specific, 220 
non-targeting AllStars siRNA duplex (QIAGEN, Valencia, CA) was used as negative control 221 
treatment. HPAEC were grown to 70% confluence, and the transfection of siRNA (final 222 
concentration 50 nM) was performed using DharmaFECT1 transfection reagent (Dharmacon 223 
Research, Lafayette, CO) according to manufacturer's protocol. Forty eight hours post-224 
transfection cells were harvested and used for experiments. Additional control experiments using 225 
EC transfections with fluorescently labeled nonspecific RNA showed that this protocol allowed 226 
us to achieve 90–100% transfection efficiency. 227 
 228 
Plasmid Constructs  229 
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         Moesin constructs (wild type and phosphorylation deficient mutant) were prepared as we 230 
have previously described (9).  231 
 232 
Immunofluorescent staining  233 
         EC were plated on glass coverslips, grown to 70% confluence, and transfected with siRNA 234 
followed by stimulation with thrombin. Then cells were fixed in 3.7% formaldehyde solution in 235 
PBS for 10 min at 4°C, washed three times with PBS, permeabilized with 0.2% Triton X-100 in 236 
PBS-Tween (PBST) for 30 min at room temperature, and blocked with 2% BSA in PBST for 30 237 
min. Incubation with antibody of interest was performed in blocking solution for 1 h at room 238 
temperature followed by staining with either Alexa 488-, or Alexa 594-conjugated secondary Ab 239 
(Molecular Probes). Actin filaments were stained with Texas Red-conjugated phalloidin 240 
(Molecular Probes) for 1 h at room temperature. After immunostaining, the glass slides were 241 
analyzed using a Nikon video-imaging system (Nikon Instech Co., Japan) consisting of a phase 242 
contrast inverted microscope Nikon Eclipse TE2000 connected to Hamamatsu (Hamamatsu 243 
Photonics K.K., Japan) digital camera and image processor. The images were recorded and 244 
processed using Adobe Photoshop 6.0. 245 
 246 
Immunoblotting  247 
         Protein extracts were separated by 4-15% gradient SDS-PAGE, transferred to nitrocellulose 248 
or polyvinylidene difluoride membranes (30 V for 18 h or 100 V for 1.5 h), and reacted with Ab 249 
that recognizes ezrin, moesin, radixin, or other Ab of interest as indicated for individual 250 
experiments. The level of phosphorylated ERM was examined by using a single Ab that 251 
recognizes any of the three ERM proteins only when they are phosphorylated on the threonine 252 
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residue: ezrin (T567)/radixin (T564)/moesin (T558) (Cell Signaling). Immunoreactive proteins 253 
were detected with the enhanced chemiluminescent detection system (ECL) according to the 254 
manufacturer's directions (Amersham, Little Chalfont, UK). Intensities of immunoreactive 255 
protein bands were quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, 256 
CA).  257 
 258 
Statistical Analysis 259 
         Results are expressed as means ±SD of three to six independent experiments. We 260 
performed statistical comparison among treatment groups by unpaired Student’s t-test or by 261 
randomized-design two-way analysis of variance followed by the Newman-Keuls post hoc test 262 
for multiple-groups. Results with P <0.05 were considered statistically significant. 263 
 264 
Results 265 
Expression of ezrin, radixin and moesin in HPAEC 266 
         The mRNA expression profiles of individual ERMs were analyzed for confluent human 267 
pulmonary EC. RT-PCR analysis reveals differential expression with highest relative expression 268 
of moesin and lowest expression of radixin (Fig.1).   269 
 270 
 Thrombin induces threonine phosphorylation of ERM via a PKC-mediated pathway 271 
         To elucidate the effect of thrombin on phosphorylation of ERM at its critical C-terminal 272 
threonine, confluent human pulmonary EC were stimulated with thrombin (0.5 U/ml), and 273 
threonine phosphorylation then was evaluated by Western blot analysis utilizing phospho-274 
specific ERM antibody (phospho-Ezrin Thr567/Radixin Thr564/Moesin Thr558). Thrombin 275 
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induced the sustained threonine phosphorylation of ERM, which reached maximum levels by 5 276 
min and remained elevated for at least 120 min (Fig. 2).  277 
         Because several kinases, including members of PKC, ROCK, GRK2, p38, Mst4 and LOK, 278 
have been reported to phosphorylate the regulatory C-terminal threonine residue of ERM 279 
proteins in various systems (3, 10, 35, 40, 59, 67), experiments were performed to determine the 280 
signaling mechanisms leading to ERM phosphorylation in pulmonary EC upon thrombin 281 
treatment.  The role of different kinases was examined by using specific pharmacological 282 
inhibitors: PKC-specific inhibitor Ro-31-7549, p38 MAPK inhibitor SB203580, Rho-associated 283 
protein kinase (ROCK) inhibitor Y-27632, phosphoinositide 3-kinases (PI3Ks) inhibitor 284 
LY294002, and chelator of intracellular Ca2+ BAPTA (Fig. 3). In our experiments, pretreatment 285 
with Ro-31-7549 effectively prevented the increase in ERM phosphorylation induced by 286 
thrombin (Fig. 3A), suggesting that this increase is PKC-dependent. Pretreatment with BAPTA, 287 
a chelator of intracellular Ca2+, partially inhibited ERM phosphorylation (Fig. 3A). We next 288 
explored whether additional signaling pathways previously reported to participate in ERM 289 
regulation are involved in thrombin-induced ERM phosphorylation.  Pretreatment with Y-27632 290 
did not exert a significant effect on ERM threonine phosphorylation. At the same time, 291 
phosphorylation of myosin light chain (MLC), regulated by the ROCK/myosin phosphatase-292 
dependent signaling pathway, was significantly attenuated in ECs preincubated with Y-27632 293 
(Fig. 3A). Because of the critical role of Rho activation, through its downstream effector ROCK, 294 
in thrombin-induced EC barrier dysfunction, we next studied how the inhibition of ROCK affects 295 
ERM phosphorylation using the more potent and selective cell-permeable pharmacological 296 
ROCK inhibitor H-1152. Pretreatment with either H-1152 or Y-27632 did not exert significant 297 
effects on ERM threonine phosphorylation after thrombin (Fig. 3B). In addition, preincubation of 298 
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HPAEC with the pharmacologic inhibitor of p38 MAPK SB203580 did not significantly affect 299 
ERM phosphorylation (Fig. 3A, B).  300 
         The role of PKC isoforms was examined by using two alternative approaches: pretreatment 301 
of EC with PKC-specific pharmacological inhibitors and using isoform-specific siRNAs. We 302 
utilized three PKC-specific pharmacological inhibitors that have different IC50 values for 303 
different PKC isoforms, bisindolylmaleimide I (BIM), Go 6976, and Ro-31-7549. Bis I, Ro-31-304 
7549 and Go 6970 are all competitive inhibitors for the ATP-binding site of PKC (39, 63, 69). 305 
BIM inhibits the conventional PKC isoforms α, βI, βII and γ (activated by phosphatidylserine, 306 
diacylglycerol and Ca2+) with similar potency (IC50 = 10 nM) (63), and the unconventional 307 
isoforms δ and ε (require phosphatidylserine and diacylglycerol but are Ca2+-independent) and 308 
the atypical isoform ζ (require only phosphatidylserine), to a lesser extent (39). In contrast to 309 
BIM, Ro-31-7549 has slight selectivity for the α isoform (IC50 = 53 nM), but also affects βI, βII, 310 
ε and γ (69). Go 6970 inhibits Ca2+-dependent PKC isoforms α and βI (39).  In our experiments, 311 
pretreatment with Ro-31-7549, BIM and Go 6970 effectively suppressed ERM phosphorylation 312 
induced by thrombin (Fig. 3C). These pharmacological PKC inhibitor data combined with the 313 
BAPTA data suggest that multiple PKC isoforms may be required. Furthermore, our experiments 314 
demonstrate that incubation with Go 6976 significantly inhibited phosphorylation of MLC at 315 
Thr18 and Ser19 induced by thrombin (Fig. 3C).  316 
To better characterize the PKC isoforms involved in ERM phosphorylation after 317 
thrombin, activation of individual PKC kinases was explored using isoform-specific phospho-318 
antibodies. Thrombin stimulation (0.5 U/ml) of HPAEC significantly increased phosphorylation 319 
of PKCβ (Thr500) (Fig. 4A), PKCγ (Thr514) (Fig. 4B), PKCε (Ser729) (Fig. 4C), 320 
PKCζ (Thr410) (Fig. 4D), PKCθ (Thr538) (Fig. 4E), and PKCδ (Tyr311) (Fig. 4F). Previous 321 
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studies have indicated that these PKC isoforms play important roles in thrombin- and other 322 
inflammatory agonists- (TNF-α, IL-1β, VEGF, hypoxia) induced modulation of endothelial 323 
permeability (16, 38, 44, 51, 53, 56, 61, 62, 70) and therefore were selected for further 324 
experimentation using isoform-specific siRNA. We first validated that these siRNAs efficiently 325 
inhibit their respective targets: 65±7% depletion of PKCβ, 97±2.2% depletion of PKCδ, 326 
75.5±2.4% depletion of PKCθ, 92±2.5% depletion of PKCε, and 65±2.5% depletion of PKCγ 327 
[Fig. 5, see also (1)]. It is important to note the limitations of this siRNA approach as it does not 328 
provide 100% protein suppression and therefore some, albeit reduced protein function likely 329 
remains. EC were transfected with siRNA for PKCβI, PKCγ, PKCε, PKCζ, PKCθ or PKCδ and 330 
then stimulated with thrombin to determine the effects on ERM threonine phosphorylation. 331 
Depletion of individual PKCγ, PKCε, PKCζ, PKCθ or PKCδ isoforms significantly reduced 332 
ERM phosphorylation after thrombin (Fig. 6 A, B). To further clarify the involvement of PKC 333 
activity in thrombin-induced ERM and MLC phosphorylation, we pursued simultaneous 334 
depletion of several PKC isoforms (pan-PKC) via siRNA. Combined depletion of several PKC 335 
isoforms markedly reduced ERM phosphorylation after thrombin (Fig. 6C, D), suggesting 336 
possible cooperative regulation in this phosphorylation response.  Moreover, downregulation of 337 
pan-PKC significantly attenuates thrombin-induced MLC di-phosphorylation (Fig. 6C, E), 338 
suggesting that multiple PKC isoforms may be involved. Taken together, these data indicate that 339 
multiple PKC isoforms (conventional, unconventional and atypical) likely participate in 340 
thrombin-induced ERM and MLC phosphorylation. One limitation of these data is that combined 341 
silencing of multiple PKC isoforms may result in some nonspecific effects, e.g. nonspecific 342 
activation or/and inhibition of other signaling pathways. Therefore, further studies utilizing 343 
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alternative approaches (e.g. isoform specific PKC peptide inhibitors) will be needed to verify 344 
these findings. 345 
 346 
Effects of ERM depletion on thrombin-induced ERM threonine and MLC phosphorylation 347 
         Numerous studies have reported a critical role for activation of the contractile apparatus in 348 
specific models of agonist-induced EC barrier dysfunction [reviewed in (12)]. A key contractile 349 
event in thrombin-induced barrier dysfunction is the phosphorylation of regulatory MLC, 350 
catalyzed by Ca2/CaM-dependent MLCK (60, 72) and regulated by small GTPase Rho. There are 351 
no antibodies currently available that specifically differentiate among the C-terminal phospho-352 
threonines of individual ERM proteins. Therefore, to assess the contribution of individual 353 
proteins in total ERM threonine phosphorylation and their roles in MLC phosphorylation after 354 
thrombin, we used siRNAs targeting ezrin, radixin, and moesin. We first validated that these 355 
siRNAs efficiently and specifically inhibited their respective targets (1). Pulmonary EC were 356 
then transfected with nonspecific siRNA, or siRNA for moesin, radixin, or siRNA for the 357 
combination of ezrin, radixin and moesin (pan-ERM), and then stimulated with thrombin. Pan-358 
ERM and MLC phosphorylation was evaluated by Western blot analysis utilizing phospho-359 
specific ERM antibody and phospho-myosin light chain 2 (Thr18/Ser19) antibody (di-phospho-360 
MLC). In contrast to cells transfected with nonspecific RNA, depletion of moesin alone or 361 
downregulation of pan-ERM significantly reduced time-dependent ERM and MLC 362 
phosphorylation after thrombin (Fig. 7A, D). Thrombin-induced ERM and MLC phosphorylation 363 
was partially attenuated by depletion of ezrin (Fig. 7C). In contrast, depletion of radixin did not 364 
have any significant effect on MLC phosphorylation after thrombin (Fig. 7B). Radixin siRNA 365 
partially, but significantly, reduced ERM threonine phosphorylation (Fig. 7B). Taken together, 366 
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these data indicate that in pulmonary EC thrombin induces primarily threonine phosphorylation 367 
of moesin, followed by ezrin, and then radixin. These data also suggest that activated moesin and 368 
to a lesser degree ezrin, but not radixin, may play a role in MLC phosphorylation induced by 369 
thrombin via the ROCK/myosin phosphatase signaling pathway. 370 
 371 
Role of ERM in thrombin-induced lung EC hyperpermeability  372 
         To evaluate the functional involvement of individual ERM proteins in thrombin-induced 373 
EC barrier dysfunction, we measured changes in TER, a highly sensitive in vitro assay of 374 
permeability, in lung EC treated with nonspecific siRNA or those treated with siRNA for ezrin, 375 
radixin, or moesin (either singly or in combination). Comparing the data expressed as normalized 376 
resistance (Fig. 8) to the time course of ERM threonine phosphorylation (Fig. 2) demonstrates 377 
that the increase in ERM phosphorylation is highly correlated with the onset of thrombin-378 
induced hyperpermeability.  Depletion of individual ERM proteins does not affect basal 379 
permeability. However, the thrombin-induced decrease in TER is markedly attenuated in EC 380 
transfected with moesin or pan-ERM-specific siRNA (Fig. 8A, D and E) compared with cells 381 
transfected with nonspecific RNA duplexes. The initial thrombin-induced decrease in TER was 382 
attenuated by siRNA depletion of ezrin, but this intervention markedly enhanced the recovery 383 
above baseline in the later stage (Fig. 8C, E). In contrast, depletion of radixin slightly augments 384 
the decrease in TER during the early phase and attenuates the later recovery phase after thrombin 385 
(Fig. 8B, E) compared with agonist-stimulated cells transfected with nonspecific RNA. These 386 
data clearly indicate differential roles for individual ERM proteins in mediating thrombin-387 
induced lung EC hyperpermeability.  388 
 389 
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Role of PARs in thrombin-induced ERM phosphorylation 390 
         In human pulmonary EC, activation of PAR1 and PAR2 promotes PKC and RhoA 391 
activation and triggers the endothelial barrier-disruptive response (7, 22, 37, 43). We next 392 
utilized PAR1-specific blocking antibodies ATAP2 and WEDE15, and PAR1 (TFLLR-NH2) and 393 
PAR2 (SLIGRL-NH2) selective agonist peptides, to determine the roles of these receptors in 394 
thrombin-induced threonine phosphorylation of ERM.  HPAEC preincubation with both ATAP2 395 
and WEDE15, either singly or in combination, significantly decreased ERM phosphorylation 396 
after thrombin relative to controls (Fig. 9).  Stimulation of EC with both TFLLR-NH2 and 397 
SLIGRL-NH2 augmented the phospho-ERM signal (Fig. 10) compared with cells treated with 398 
control peptides. Interestingly, incubation of EC with a combination of TFLLR-NH2 and 399 
SLIGRL-NH2 markedly enhanced ERM phosphorylation, compared with cells treated with these 400 
two agonists alone (Fig. 10), suggesting that both PAR1 and PAR2 may have additive or 401 
synergistic effects in this phosphorylation response.    402 
 403 
Involvement of ERM in thrombin-induced EC cytoskeletal remodeling 404 
         Compromised barrier function induced by thrombin is tightly associated with actin 405 
cytoskeletal rearrangements, F-actin stress fiber formation, increased MLCK-catalyzed MLC 406 
phosphorylation spatially co-localized with stress fibers, actomyosin contraction, opening of 407 
paracellular gaps, and hyperpermeability (12, 43). Within this context, the distribution of 408 
phosphorylated ERM in EC before and after thrombin treatment was examined via 409 
immunofluorescence. Before thrombin treatment, minimal phosphorylated ERM was observed in 410 
the cytoplasm of pulmonary EC. In some areas of quiescent monolayers, phospho-ERM 411 
localized in the spike-like structures overlapping the cell-cell contact areas (Fig. 11, image a, 412 
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arrow 1). Stimulation with thrombin induced an increase in the amount of phosphorylated ERM, 413 
consistent with immunoblotting studies (Fig. 2). During the early response (5 minutes after initial 414 
stimulation),  phosphorylated ERM was localized primarily at the cell periphery and spike-like 415 
areas (Fig. 11, image b, arrows 1 and 2) with a smaller amount of phospho-ERM also observed 416 
in the cytoplasm (Fig. 11, image b). In contracting EC (15 minutes after initial challenge) the 417 
phospho-ERM signal markedly increased in the peripheral cytoplasmic areas (Fig. 11, image c). 418 
During partial restoration phases (60 and 120 minutes after the initial challenge), phosphorylated 419 
ERM primarily localized in cytoplasmic areas and spike-like structures that were originally seen 420 
in quiescent cells (Fig. 11, images d, e), but the overall level of phosphorylated ERM appeared 421 
slightly elevated compared to baseline. These dynamic changes in phosphorylated ERM 422 
localization during the phases of active cell contraction and partial barrier restoration indicate 423 
that ERM proteins may play a role in both processes. The observation that phosphorylated ERM 424 
proteins were primary concentrated along the EC periphery upon thrombin treatment led us to 425 
examine the role of these proteins in modulating endothelial cytoskeletal rearrangements that 426 
occur during thrombin-induced EC hyperpermeability. 427 
         In the next series of experiments we analyzed the effect of ERM depletion on the human 428 
endothelial actin cytoskeleton. EC were transfected with nonspecific RNA duplex 429 
oligonucleotides (Fig. 12) or ERM-specific siRNA (Fig. 12) followed by thrombin challenge (15 430 
min, 0.5 U/ml). Double immunofluorescent staining using Texas red phalloidin to visualize F-431 
actin and di-phospho-MLC antibody to detect phosphorylated MLC was performed.  432 
Unstimulated EC transfected with ezrin-, radixin-, or moesin-specific siRNAs, either individually 433 
or in combination, demonstrated no significant differences in the organization of actin 434 
cytoskeleton and levels of MLC phosphorylation compared with control EC exposed to 435 
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nonspecific RNA (Fig. 12, panel A, images a-n). However, thrombin stimulation of EC treated 436 
with nonspecific RNA induced robust F-actin stress fiber and gap formation and accumulation of 437 
di-phospho-MLC (Fig. 12, panel B, images c and d), which were nearly abolished by the 438 
combination of siRNAs for radixin/ezrin/radixin (pan-ERM depletion), or by siRNA for moesin 439 
alone. In contrast, radixin depletion alone slightly enhanced stress fiber formation and MLC 440 
phosphorylation (Fig.12, panel B, images k and l). We next explored the effects of 441 
overexpression of a phosphorylation-deficient mutant of moesin (Thr558Ala) on EC cytoskeletal 442 
organization. Scanning densitometry (Fig. 13A) demonstrated relatively equivalent expression of 443 
the wild type and mutant moesin in EC. Monolayers overexpressing mutant moesin exhibited 444 
decreased F-actin stress fibers after thrombin and prominent cortical actin compared to EC 445 
overexpressing wild type moesin (Fig.13, panel B, images c, g). These data together demonstrate 446 
that ERM proteins are downstream targets of thrombin-induced signaling mechanisms and play 447 
an essential and differential role in the regulation of the endothelial actomyosin cytoskeleton. 448 
 449 
Discussion 450 
         Prior work has revealed that the procoagulant serine protease thrombin induces endothelial 451 
barrier compromise through G protein-coupled Ca2+ mobilization, MLCK, PKC and RhoA 452 
activation, which produces cytoskeletal rearrangement, dissociation of endothelial cell-cell 453 
junctions as well as cytoskeleton contraction resulting in paracellular hyperpermeability (12, 27, 454 
33, 34, 43, 45, 66).  Although ERM proteins act as signal transducers for agonists that induce 455 
cytoskeletal remodeling (14), the role of ERM in barrier regulation by thrombin is unknown. 456 
Moesin is the most expressed ERM protein in several types of endothelial cells (4, 24, 30, 35). 457 
Here we demonstrate that moesin is the most abundant ERM expressed in HPAEC as measured 458 
by mRNA content, with radixin being the least expressed. We previously have shown that the 459 
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angiogenic sphingolipid S1P induces ERM phosphorylation on a conserved threonine residue 460 
critical for ERM activation via a pathway that requires PKC, Rac1, Rho A, and p38 MAPK (1). 461 
We also have previously demonstrated that phosphorylation of ERM in response to the 462 
microtubule disruptor 2-methoxyestradiol (2ME) occurs in a p38/PKC-dependent manner 463 
(9). We therefore explored whether the ERM family of proteins plays a role in modulating the 464 
thrombin-induced endothelial barrier response. Our data demonstrate that thrombin increases 465 
ERM phosphorylation at a critical regulatory threonine site in HPAEC monolayers and strongly 466 
suggest important roles for the ERM proteins in mediating endothelial barrier dysfunction by 467 
thrombin. This phosphorylation requires thrombin-induced signaling pathways that include 468 
activation of PKC isoforms, but it is not regulated in a RhoA/ROCK- or p38-dependent manner. 469 
Our results differ from those in our (1, 9), and others previous studies (23, 35, 68), in which the 470 
phosphorylation of  ERM was PKC-, RhoA/ROCK- and-p38-dependent in response to S1P, 471 
PKC- and RhoA/ROCK-dependent in response to 2ME and TNF-α, and RhoA/ROCK-472 
dependent in response to advanced glycation end products (AGE). Together, these observations 473 
suggest that ERM may be phosphorylated at the critical C-terminal threonine site by different 474 
upstream pathways that can vary from endothelium to endothelium and from stimuli to stimuli.  475 
         We and others previously have demonstrated that several PKC isoforms - conventional, 476 
unconventional and atypical—are likely to phosphorylate the C-terminal threonine residue of 477 
ERM proteins (1, 35, 52, 67). Our data now demonstrate that PKC isoforms ζ, γ, ε, θ and 478 
δ, which previously have been demonstrated to play roles in inflammation-induced changes in 479 
endothelial permeability (16, 44, 53, 56, 61, 62, 70), participate in thrombin-induced ERM 480 
phosphorylation at the C-terminal threonine site in human pulmonary EC (Figure 6). Moreover, 481 
our data indicate that these isoforms may synergistically regulate both ERM threonine and MLC 482 
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phosphorylation (Fig. 6C, D).  One of the key events in the signaling cascade triggered by 483 
thrombin binding to PAR receptors is Ca2+-dependent activation of PKC and Ca2+/calmodulin-484 
dependent MLCK, which phosphorylates myosin light chain (MLC) (12, 37). RhoA and its 485 
effector ROCK indirectly regulate MLCK activation and MLC phosphorylation and therefore 486 
also mediate endothelial hyperpermeability in response to thrombin (8, 49, 64).  The 487 
RhoA/ROCK pathway is one of the downstream signals activated by PKC (8). Data 488 
demonstrating that ERM are phosphorylated by PKC in response to thrombin prompted us to 489 
examine the time-dependent phosphorylation status of individual ERM and whether ERM play a 490 
role in MLC phosphorylation after thrombin. The effects of ERM siRNA treatment, either singly 491 
or in combination, on the phosphorylated ERM and MLC phosphorylation before or after 492 
thrombin treatment were examined. We discovered that all three proteins were phosphorylated; 493 
however, knockdown of moesin alone or all three ERM proteins together significantly reduced 494 
thrombin-induced ERM and MLC phosphorylation (0-90 minutes).  In contrast, depletion of 495 
radixin did not have any significant effect on MLC phosphorylation while slightly reducing 496 
ERM threonine phosphorylation after thrombin. Depletion of ezrin partially attenuated thrombin-497 
induced ERM and MLC phosphorylation. Importantly, these data demonstrate differential roles 498 
for the ERM proteins in response to thrombin, despite their structural similarities and reported 499 
functional redundancy. These data also clearly suggest that moesin and to a lesser degree ezrin, 500 
but not radixin, are critically involved in MLC phosphorylation after thrombin.  501 
The underlying mechanism through which moesin and ezrin regulate MLC phosphorylation 502 
remains to be determined. ERM proteins are known to activate the Rho signaling in cell adhesion 503 
regulation via association with Rho regulator Rho GDP-dissociation inhibitor (GDI) (58). Our 504 
data indicate that ERM may be upstream of MLC phosphorylation. Depletion of PKC isoforms 505 
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(Fig. 6A-D) indicated that PKC-dependent moesin and ezrin phosphorylation on regulatory C-506 
terminal threonine is involved in thrombin-induced RhoA activation and subsequent increased 507 
MLC phosphorylation. In addition, phosphorylation of moesin or/and ezrin at sites other then C-508 
terminal threonine may contribute to this activation. For example, several additional sites have 509 
been reported for ezrin (threonine 235, tyrosines 145 and 353) (36, 73), but the functional roles 510 
of phosphorylation at these sites are still unclear. Interestingly, as we recently have been reported 511 
(31), each ERM protein has a distinct binding ability toward the subunits (CSIβ and MYPT) of 512 
MLC phosphatase (MLCP), a type 1 protein phosphatase (PPase 1) that regulate reversible 513 
phosphorylation of the MLC in intercellular gap formation and barrier dysfunction of EC. Our 514 
data demonstrated that the catalytical subunit CSIβ preferably bound to moesin, while the band 515 
that corresponds to ezrin detected in CSIβ immunoprecipitates is faint. In contrast, radixin did 516 
not bind to CSIβ, but strongly interacted with MLCP targeting subunit MYPT I. It is possible, 517 
that in addition to RhoA activation after thrombin, moesin may inhibit MLCP function leading to 518 
increased MLC phosphorylation. Our prior results indicated that MLCP play an important role in 519 
barrier protection in EC (31). Radixin may regulate MLCP activation through binding to MYPT 520 
I in S1P-induced barrier enhancement. Future studies will be needed to clarify the link between 521 
PKC/ERM and Rho/ROCK/MLCP pathways in thrombin-induced formation of stress fibers and 522 
increased endothelial permeability.  523 
         We next examined the role of ERM in thrombin-induced cytoskeletal changes. Thrombin 524 
induces translocation of phosphorylated ERM from the cytoplasm to EC periphery during the 525 
early stages of cells contraction and loss of monolayer integrity (Figure 11), which is consistent 526 
with previous studies (1, 9, 35). Most importantly, our data again demonstrate differential roles 527 
for the ERM proteins in response to thrombin.  Moesin exerted a particularly prominent and 528 
24 
 
essential role in the promotion of EC barrier dysfunction by thrombin, while radixin appears to 529 
have opposing effects.  This observation is consistent with recent reports describing moesin 530 
involvement in increased permeability induced by hypoxia and  truncation of monocyte 531 
chemoattractant protein 1 in the blood-brain barrier (25, 74) and AGE in human microvascular 532 
EC (23, 68). Prior data obtained using knockout mice lacking individual ERM proteins largely 533 
support the functional redundancy of the three ERM proteins (11, 32, 54). However recent 534 
studies demonstrate differential biological functioning of these proteins. For example, ezrin and 535 
moesin have distinct and critical functions in the T cell cortex during immunological synapse 536 
formation (28). Moreover, ezrin, but not moesin, is phosphorylated on tyrosine in EGF-537 
challenged human A431 cells despite tyrosine 145 conservation in both proteins (17).  In 538 
addition, moesin has a non-redundant function in lymphocyte homeostasis (26). Our recent 539 
findings also support the distinct biological roles of these proteins in agonist-mediated EC barrier 540 
responses (1). 541 
         The observation that phosphorylated ERM is mostly localized to the peripheral area in EC 542 
undergoing contraction after thrombin stimulation led us to examine the role of these proteins in 543 
modulating permeability increases. We evaluated the role of ERM in thrombin-induced 544 
hyperpermeability by measuring the TER in ERM depleted EC. The depletion of moesin alone or 545 
triple ERM siRNA knockdown significantly attenuated the increase in permeability after 546 
thrombin (Figure 8A, D and E). Ezrin knockdown also attenuated the decrease in TER induced 547 
by thrombin, but to a lesser degree then moesin (Fig. 8C, E). In contrast, radixin depletion leads 548 
to a slight increase in permeability during the early phase and delayed recovery during the later 549 
phase of thrombin–mediated decreases in TER (Fig. 8B, E). These results suggest that ERM are 550 
differentially involved in the development of thrombin-induced permeability with moesin and 551 
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ezrin promoting barrier permeability during the phase of active contraction (5-60 minutes of 552 
treatment with thrombin). In contrast, despite the lower level of expression compare to moesin 553 
and ezrin, radixin exerted a particularly prominent and essential role in the promotion of EC 554 
barrier function in the restoration phase (60-120 minutes of treatment). 555 
         In EC, thrombin-induced activation of PAR1 receptor initiate signaling through Gq- and 556 
G12/13-coupled Ca2+ mobilization, PKC and RhoA activation, and MAPK signaling  (5, 7, 27). In 557 
addition, thrombin transactivates PAR2 through PAR1 (48). We next used PAR1 (TFLLR-NH2), 558 
PAR2 (SLIGRL-NH2) selective agonists and the PAR1-specific blocking antibodies ATAP2 and 559 
WEDE15 to determine the role of PARs in thrombin-induced threonine phosphorylation of 560 
ERM.  Our data indicate that thrombin primarily induces ERM threonine phosphorylation in 561 
pulmonary EC by combined activation of both PAR1 and PAR2. 562 
 563 
Conclusion 564 
          The present study demonstrates that thrombin induces PKC-dependent ERM 565 
phosphorylation on a critical threonine residue (Ezrin-567, Radixin-564, Moesin-558) and 566 
translocation of phosphorylated ERM to the EC periphery.   ERM phosphorylation is mediated 567 
by the combined actions of PAR1 and PAR2. Thrombin-induced barrier dysfunction in 568 
pulmonary endothelium is associated with remodeling of the actin cytoskeleton that increases 569 
permeability. ERM proteins are critically involved in the barrier-disruptive response induced in 570 
the endothelium by thrombin and may modulate cytoskeletal changes and barrier 571 
hyperpermeability via such intermediate signaling events as PKC mediated RhoA/ROCK-572 
dependent signaling. Our data demonstrate that depletion of either moesin alone, or of all three 573 
ERM proteins, attenuates thrombin-induced F-actin cytoskeleton rearrangement, paracellular gap 574 
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formation, MLC phosphorylation and decrease in TER. In contrast, radixin depletion has the 575 
opposite effect on barrier function. Based on these results and our prior data (1), we propose the 576 
following model of ERM-dependent signaling in thrombin- and S1P-treated ECs (Fig. 14): 577 
thrombin treatment induces PAR1 and PAR2-mediated C-terminal threonine phosphorylation 578 
primarily of moesin and ezrin by PKC and PIP2. Recently it has been reported that 579 
phosphorylation of the RhoA activator - guanine nucleotide exchange factor p115RhoGEF by 580 
PKC-α mediates TNF-α-induced RhoA activation and subsequent barrier dysfunction in mouse 581 
brain microvascular endothelial cells (51). We hypothesize that PKC isoforms may 582 
simultaneously phosphorylate both moesin and ezrin and p115RhoGEF. Activated moesin and 583 
ezrin may displace RhoGDI from RhoA, allowing p115RhoGEF mediated RhoA activation by 584 
GDP to GTP exchange. Increased intracellular concentration of Ca2+ activates MLCK. RhoA and 585 
MLCK phosphorylate MLC, allowing EC contraction and reorganization of the cytoskeleton, 586 
resulting in endothelial barrier dysfunction. In contrast, S1P induces S1PR1-mediated radixin 587 
activation (primarily), resulting in Rac1 activation. Activated Rac1 via its downstream target 588 
PAK1 induces actomyosin remodeling, including formation of a prominent cortical actin rim, 589 
which stabilizes cell-cell junctions, peripheral accumulation of phosphorylated MLC, and 590 
disappearance of central stress fibers, resulting in endothelial barrier enhancement.  Thus, despite 591 
their structural similarities and reported functional redundancy, the ERM proteins differentially 592 
modulate thrombin-induced changes in lung EC cytoskeleton and permeability. These results 593 
advance our mechanistic understanding of EC barrier regulation, identify the ERM family as 594 
potential targets for therapeutic manipulation in this clinically important physiologic process and 595 
extend previous knowledge about the involvement of PKC and ERM in endothelial barrier 596 
regulation. 597 
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Figure Legends 851 
Figure 1. Relative quantity of moesin (MSN), ezrin (EZR), and radixin (RDX) mRNA in 852 
HPAEC. Total RNA was isolated from human pulmonary artery endothelial cells (HPAEC) and 853 
quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR) was performed 854 
using target gene specific primers and probes and the relative amounts expressed using standard 855 
curve method as described in Methods. Each value represents the mean of triplicates. 856 
 857 
Figure 2. Time-dependent effects of thrombin on threonine phosphorylation of ERM. (A) 858 
Confluent HPAEC were treated either with control vehicle or thrombin (0.5 U/ml) for the 859 
indicated times, and phosphorylated ERM (phospho-Ezrin (Thr567)/Radixin (Thr564)/Moesin 860 
(Thr558) was detected via immunoblotting. (B) The bar graph represents relative densitometry. 861 
Data are presented as fold changes in phosphorylated ERM over vehicle-treated control and 862 
expressed as means ± S.E. from three independent experiments. *P < 0.05 vs. unstimulated 863 
control. 864 
 865 
Figure 3. Thrombin-induced ERM phosphorylation requires activation of PKC. HPAEC 866 
were pretreated with either control vehicle or the following inhibitors:  PKC inhibitors Ro-31-867 
7549 (10 µM, A, C) for 30 min, bisindolylmaleimide (BIM, 1 µM, C) for 30 min,  Go6976 (1 868 
µM, C) for 1 h,  Ca(2+) chelator BAPTA-AM (25 µM, A) for 1 h, p38 kinase inhibitor 869 
SB203580 (20 μM, A, B) for 30 min, Rho kinase inhibitors Y-27632 (10 µM, A, B) for 1 h and 870 
H-1152 (3 μM, B) for 1 h, PI3 Kinase inhibitor LY294002 ( 10 μM, A) for 1 hr. EC were then 871 
stimulated with EBM-2 medium alone or thrombin (0.5 U/ml) for the indicated time. 872 
Phosphorylation of ERM proteins and MLC were analyzed by immunoblotting of cell lysates 873 
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with phospho-ERM (as in Fig. 2) or di-phospho-MLC (Thr18/Ser19) specific Abs. GAPDH or β-874 
actin Abs were used as a normalization control. Rearranged lanes from the same blot are outlined 875 
by vertical dotted line. Results of scanning densitometry of Western blots are shown as fold 876 
changes of ERM or MLC phosphorylation relative to vehicle treated EC stimulated by thrombin. 877 
Results are representative of 3-6 independent experiments. Values are means ± S.E. *, 878 
significantly different from cells treated with vehicle (p < 0.05); **, significantly different from 879 
cells stimulated with thrombin (p < 0.05).  880 
 881 
Figure 4. Effects of thrombin on phosphorylation of PKC isoforms in HPAEC.  Confluent 882 
HPAEC were treated either with control vehicle or thrombin (0.5U/ml) for the indicated times, 883 
and phosphorylated PKCβ (A), PKCγ (B), PKCε (C),  PKCζ (D), PKCθ (E), and PKCδ (F) were 884 
detected via immunoblotting. Bar graphs represent relative densitometry of fold changes in 885 
phosphorylated PKC isoforms after thrombin relative to vehicle-treated control and expressed as 886 
means ± S.E. from three independent experiments. *, significantly different from cells treated 887 
with EBM-2 (p < 0.05); #, significantly different from cells treated with EBM-2 (p < 0.01).  888 
 889 
Figure 5. Depletion of PKC isoforms by siRNA. PKCε (A) and PKCγ (B) depletion were 890 
induced by specific siRNA duplexes and assessed for silencing effects by immunoblotting with 891 
appropriate Ab, as compared with treatment with nonspecific (ns) siRNA. Immunoblotting with 892 
β-actin Ab was used as a normalization control. Rearranged lanes from the same blot are outlined 893 
by vertical dotted line. Quantitative analysis of protein expression was performed by scanning 894 
densitometry and expressed in relative density units (RDU). Results are means ± S.E. for three 895 
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independent experiments. #, significant difference (p < 0.01) when compared with cells treated 896 
with ns siRNA. 897 
 898 
Figure 6. Depletion of PKC isoforms inhibits thrombin-induced ERM and MLC 899 
phosphorylation. Confluent HPAEC were incubated with non-specific, PKCβI-, PKCζ-, PKCθ-900 
, PKCδ-, PKCγ- and PKCε- specific siRNA (A) or with non-specific, combinations of  PKCδ- 901 
and PKCε-, combinations of PKCγ- , PKCδ- and PKCε-  and combinations of PKCβI - , PKCθ- 902 
and PKCζ-  specific siRNAs (C) as described in Methods, and then stimulated by thrombin (0.5 903 
U/ml, 5 min) or vehicle. Total lysates were analyzed by immunoblotting for phospho-ERM or di-904 
phospho-MLC (Thr18/Ser19). Immunoblotting with β-tubulin Ab was used as a normalization 905 
control. Rearranged lanes from the same blot are outlined by vertical dotted line. (B, D, E) The 906 
bar graphs represent relative densitometry of fold changes in phosphorylated ERM and MLC 907 
after thrombin relative to vehicle-treated control.  Results are means ± S.E. of four independent 908 
experiments. *, significantly different from cells treated with ns siRNA without thrombin (p < 909 
0.01); #, significantly different from cells treated with ns siRNA without thrombin (p < 0.05). **, 910 
significantly different from cells treated with ns siRNA and thrombin (p < 0.05). 911 
 912 
Figure 7. Effects of ERM depletion on thrombin-induced ERM and MLC phosphorylation. 913 
Confluent HPAEC were incubated with non-specific, moesin- (panel A), radixin- (panel B), 914 
ezrin-specific (panel C) or combined siRNAs for ezrin, radixin, and moesin (panel D) as 915 
described in Methods then stimulated by thrombin (0.5 U/ml, 5 min) or vehicle. Total lysates 916 
were analyzed by immunoblotting with phospho-ERM or di-phospho-MLC (Thr18/Ser19) Abs. 917 
Immunoblotting with β-tubulin Ab was used as a normalization control. The bar graphs 918 
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represents relative densitometry of fold changes in phosphorylated ERM and MLC after 919 
thrombin relative to vehicle-treated control.  Results are means ± S.E. of three independent 920 
experiments. *p<0.05, compared with corresponding pretreatment vehicle control. 921 
Figure 8. Effects of ERM depletion on thrombin-induced endothelial barrier 922 
hyperpermeability. EC grown in chambers on gold microelectrodes were transfected with 923 
siRNA for moesin (panel A), radixin (panel B), ezrin (panel C), combined siRNAs for ezrin, 924 
radixin, and moesin (panel D), or treated with nonspecific (ns) siRNA, as described in Methods 925 
and used for transendothelial electrical resistance (TER) measurements. At time = 0, cells were 926 
stimulated with thrombin (0.5 U/ml) or vehicle control. Shown are pooled data of 5 independent 927 
experiments. The bar graph (E) depicts pooled TER data (n = 5) as maximal value of normalized 928 
TER elevation above base line achieved within 30 min ± S.E. *, significantly different from cells 929 
treated with ns siRNA reagent without thrombin (p < 0.05); **, significantly different from 930 
control cells stimulated with thrombin (p < 0.05). 931 
 932 
Figure 9. Effects of PAR1 blocking antibodies on thrombin-induced ERM phosphorylation. 933 
(A) HPAEC were pretreated for 1 hour with either control vehicle or the PAR1 blocking Abs 934 
ATAP2 (25 μg/ml) or WEDE15 (25 μg/ml) or with combination of ATAP2 and WEDE15, then 935 
stimulated by thrombin (0.5 U/ml, 5 min) or vehicle. Total lysates were analyzed by 936 
immunoblotting for phospho-ERM. Immunoblotting with β-actin Ab was used as a 937 
normalization control. (B) The bar graph represents relative densitometry of fold changes in 938 
phosphorylated ERM after thrombin relative to vehicle-treated control.  Results are means ± S.E. 939 
of four independent experiments. *, significantly different from cells treated with ns siRNA 940 
without S1P (p < 0.05); #, significantly different from cells treated with ns siRNA without 941 
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thrombin (p < 0.01). **, significantly different from cells treated with ns siRNA and thrombin (p 942 
< 0.05). 943 
 944 
Figure 10. Effects of PAR1 and PAR2 selective agonists on thrombin-induced ERM 945 
phosphorylation. (A) EC were pretreated for 5 minutes with thrombin (0.5 U/ml), PAR1 946 
selective agonist TFLLR-NH2 (50 μM), PAR2 selective agonist SLIGRL-NH2 (50 μM) or 947 
combination of TFLLR-NH2 and SLIGRL-NH2. Pretreatment with vehicle and reversed amino 948 
acid sequence peptides RLLFT-NH2 and LRGILS-NH2 used as controls. (B) The bar graph 949 
represents relative densitometry of fold changes in phosphorylated ERM after thrombin, TFLLR-950 
NH2 or SLIGRL-NH2 relative to vehicle-treated control.  Results are means ± S.E. of three 951 
independent experiments. *p<0.05, compared with corresponding pretreatment controls. 952 
 953 
Figure 11. Distribution of phospho-ERM in EC after thrombin.  EC grown on glass cover 954 
slips and treated with 0.5 U/ml thrombin for indicated time (images b-e) or non treated control 955 
cells (image a) were subjected to immunofluorescent staining with anti-phospho-ERM Ab. The 956 
phospho- ERM signal is very weak in quiescent monolayers and is evident only in spike-like 957 
structures in cell-cell border areas (image a, arrow 1). Threonine-phosphorylated ERM proteins 958 
predominantly localized to the periphery of ECs following thrombin stimulation (5-15 min, 959 
images b,c, arrow 2) and also are detectable in peripheral spike-like structures (image b, arrow 960 
1).  After 1-2 hrs phosphorylated ERM localized in spike-like structures characteristic of 961 
quiescent cells and in cytoplasm (images d,e).  Images are representative of 3 independent 962 
experiments. Scale bar = 10 µm. 963 
 964 
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Figure 12. Effects of ERM depletion on thrombin-induced cytoskeletal remodeling. HPAEC 965 
grown on glass cover slips were incubated with siRNA to ezrin, radixin, moesin, or combination 966 
of siRNAs to all three proteins, or treated with non-specific siRNA duplex as described in 967 
Methods followed by thrombin treatment (0.5 U/ml, 5 min).  ECs were subjected to double 968 
immunofluorescent staining with Texas Red phalloidin to visualize F-actin (panels A and B, 969 
upper images) and anti-pp-MLC Ab (Panels A and B, bottom images).  Incubation with siRNA 970 
to moesin (g, h) and combined siRNAs to ezrin, radixin, and moesin (o, p) almost completely 971 
abolishes thrombin-induced  F-actin stress fiber and gap formation and MLC phosphorylation 972 
compared with control (nsRNA) incubation (c, d, arrows). In contrast, pretreatment with siRNA 973 
to radixin slightly enhances the thickness of stress fibers and MLC phosphorylation (k, l, arrows) 974 
compared with incubation with nsRNA. Bar = 10 µM. Images are representative of three 975 
independent experiments. 976 
 977 
Figure 13. Effects of overexpression of the phosphorylation-deficient mutant of moesin 978 
(Thr558Ala) on thrombin-induced cytoskeletal remodeling. (A) ECs were transfected with 979 
empty vector (control), V5 tagged wild-type or mutant moesin, which were then detected via 980 
immunoblotting with V5 Ab. Results of scanning densitometry of Western blots are shown as % 981 
of moesin relative to control. Immunoblotting with β-actin Ab was used as a normalization 982 
control. (B) After transfection with vectors expressing moesin (wild-type or mutant) tagged with 983 
V5, EC were grown on glass cover slips as described in Methods followed by thrombin treatment 984 
(0.5 U/ml, 5 min). ECs were subjected to double immunofluorescent staining with Texas Red 985 
phalloidin to visualize F-actin (panels B and C, upper images) and V5 Ab (Panels B and C, 986 
bottom images).  Overexpression with mutant moesin abolishes thrombin-induced F-actin stress 987 
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fibers and induces cortical actin formation (panel C, image g) compared to EC overexpressed 988 
with wild type moesin (panel C, image c). Arrow indicates cell transfected with mutant moesin 989 
EC (panel C, image g). Images are representative of three independent experiments. Scale bar = 990 
10 µm. 991 
 992 
Figure 14. Proposed model of ERM-dependent signaling in thrombin- and S1P-challenged 993 
lung endothelium (see explanation in Conclusion). 994 
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